Medtronic's strategic investment in Pulnovo Medical's oversubscribed $100M round signals a quiet land grab in pulmonary hypertension and heart...
Tilray's Lyphe acquisition signals a deliberate commercial build for U.S. cannabis rescheduling — and most competitors are structurally unprepared...
Veeva Systems — the enterprise software giant that has long dominated clinical, regulatory, and commercial operations for life sciences...
At BIO-Europe Spring 2026, industry leaders from AstraZeneca, Kelun-Biotech, Harbour BioMed, and Panacea Capital dissected the structural forces driving...
Novo Nordisk's OpenAI partnership signals a new pharma AI arms race where pipeline economics, not just science, get rebuilt...
Trastuzumab pamirtecan just posted compelling Phase 2 numbers in HER2-expressing recurrent endometrial cancer. The science is clean. The commercial...
At BIO-Europe Spring 2026, a cross-sector panel dissected how generative AI is restructuring the business development workflow — from...
Oricell Therapeutics just closed a $110 million pre-IPO round to push its CAR-T platform into solid tumors. Investors are...
At BIO-Europe Spring 2026 in Lisbon, investors and pharma executives diagnosed Europe's biotech bottleneck not as a science deficit...
As semaglutide patents begin expiring and generic manufacturers in India and China gear up for mass production, the global...
